Case Studies in Relapsed, Refractory (Multi-Drug Resistant) Stage IV Cancer. Patients had previously progressed on standard (NCCN guideline) therapy. Patients benefited from customized therapy based on comprehensive integrated genetics and cellular analysis performed at DCGL.

1. Case Studies
in
Relapsed, Refractory
(Multi-Drug Resistant)
Stage IV Cancer

2. Executive Summary
• The following cases represent relapsed, refractory advanced stage (IV)
cancers.
• In each case, the cancer was mul -drug resistant and had progressed
following failure of mul ple lines of therapy.
• Further treatment op ons under standard of care (NCCN guidelines) were
unavailable.
• The pa ents were advised pallia ve care, without any treatment of the
disease.
• DCGL carried out comprehensive molecular gene c and cellular analysis
on pa ent’s tumor, and recommended therapy for each pa ent.

3. Index
Case No. Gender Age Cancer Type
1 Female 65 Ca Head and Neck.
2 Female 22 Ca Breast.
3 Male 53 Renal Cell Carcinoma.
4 Female 53 Ca Breast.
5 Female 49 Leiomyosarcoma.
6 Female 44 Ca Breast.
7 Male 49 Ca Thyroid.
8 Female 54 Ca Breast.
9 Male 57 Melanoma.
10 Female 44 Ca Breast.
11 Female 21 Ewing’s Sarcoma.
12 Female 50 Ca Breast.
13 Female 54 Ca Ovary.
14 Female 58 Ca Breast.

4. Case 1
Stage IV Squamous Cell Carcinoma of Cheek.
65 year old female patient
Day 0 Day 30 Day 79
BEFORE
Cancer had progressed
following lines of therapy3
AFTER
Administration of DCGL recommended
therapy led to regression of cancer.

5. Case 2
Stage IV Invasive Ductal Carcinoma of Breast (Triple Negative Breast Cancer)
22 year old female patient
BEFORE
Cancer had progressed
following lines of therapy6
Day 0 Day 34
AFTER
Administration of DCGL-
recommended therapy led
to regression of cancer.

6. Case 3
Stage IV Renal Cell Carcinoma.
53 year old male patient.
BEFORE
Cancer had progressed
following lines of therapy6
AFTER
Administration of DCGL-
recommended therapy led
to regression of cancer.

7. Case 4
Stage IV Invasive Ductal Carcinoma of Breast (Triple Negative Breast Cancer).
53 year old female patient.
BEFORE
Cancer had progressed
following lines of therapy10
Day 28Day 0
LR LR
AFTER
Administration of DCGL-
recommended therapy led
to regression of cancer.

8. Case 5
Stage IV Leiomyosarcoma.
49 year old female patient.
BEFORE
Cancer had progressed
following lines of therapy3
LR LR
Day 0 Day 91
AFTER
Administration of DCGL-
recommended therapy led
to regression of cancer.

9. Case 6
Stage IV Invasive Ductal Carcinoma of Breast.
44 year old female patient.
BEFORE
Cancer had progressed
following lines of therapy9
Day 35Day 0
LR LR
AFTER
Administration of DCGL-
recommended therapy led
to regression of cancer.

10. Case 7
Stage IV Follicular Carcinoma of Thyroid.
49 year old male patient.
BEFORE
Cancer had progressed
following lines of therapy7
Day 40 Day 72
1
AFTER
Administration of DCGL-
recommended therapy led
to regression of cancer.

11. Case 8
Stage IV Invasive Ductal Carcinoma of Breast (Triple Negative Breast Cancer).
54 year old female patient.
BEFORE
Cancer had progressed
following lines of therapy3
Day 52Day 0
LR LR
AFTER
Administration of DCGL-
recommended therapy led
to regression of cancer.

12. Case 9
Stage IV Melanoma.
57 year old male patient.
BEFORE
Cancer had progressed
following lines of therapy6
Day 19Day 0
AFTER
Administration of DCGL-
recommended therapy led
to regression of cancer.

13. Case 10
Stage IV Invasive Ductal Carcinoma of Breast (Triple Negative Breast Cancer).
44 year old female patient.
BEFORE
Cancer had progressed
following lines of therapy9
Day 0 Day 96
AFTER
Administration of DCGL-
recommended therapy led
to regression of cancer.

14. Case 11
Stage IV Ewing’s Sarcoma.
21 year old female patient.
BEFORE
Cancer had progressed
following lines of therapy10
Day 36Day 0
LR LR
AFTER
Administration of DCGL-
recommended therapy led
to regression of cancer.

15. Case 12
Stage IV Invasive Ductal Carcinoma of Breast (Triple Negative Breast Cancer).
50 year old female patient.
BEFORE
Cancer had progressed
following lines of therapy6
Day 35Day 0
LR LR
AFTER
Administration of DCGL-
recommended therapy led
to regression of cancer.

16. Case 13
Stage IV Carcinoma of Ovary.
54 year old female patient.
BEFORE
Cancer had progressed
following lines of therapy4
Day 35Day 0
LR
LR
AFTER
Administration of DCGL-
recommended therapy led
to regression of cancer.

17. Case 14
Stage IV Invasive Ductal Carcinoma of Breast (Triple Negative Breast Cancer).
58 year old female patient.
BEFORE
Cancer had progressed
following lines of therapy8
Day 34Day 0
LR LR
AFTER
Administration of DCGL-
recommended therapy led
to regression of cancer.

18. Thank you